Mesenchymal stem cell therapy - Stemedica Cell Technologies
Alternative Names: Acute myocardial infarction stem cell therapy - CardioCell; Allogeneic mesenchymal bone marrow cell therapy - Stemedica; Allogeneic mesenchymal bone marrow cells; hMSC - Stemedica Cell Technologies; Ischaemia-tolerant mesenchymal stem cell; itMSC; Marrow stromal cells - Stemedica Cell Technologies; Stemedyne™ MSC; Stroke stem cell therapy - Stemedica Cell TechnologiesLatest Information Update: 24 Jan 2023
At a glance
- Originator Stemedica Cell Technologies
- Developer CardioCell; Pulthera; S.N. Fyodorov Eye Microsurgery Complex; StemCutis; Stemedica Cell Technologies
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - SARS-CoV-2 acute respiratory disease
Highest Development Phases
- Phase II Chronic heart failure; Dementia; SARS-CoV-2 acute respiratory disease; Stroke
- Phase I/II Skin aging
- Preclinical Lung disorders
- No development reported Diabetic retinopathy; Myocardial infarction
Most Recent Events
- 19 Jan 2023 US FDA approves IND application for allogeneic mesenchymal stem cells in Ischemic stroke before January 2023
- 19 Jan 2023 Stemedica plans a phase IIb/III trial for Ischemic stroke in USA (IV)
- 28 Jun 2021 No recent reports of development identified for preclinical development in Myocardial-infarction in USA (IV, Injection)